why choose us

First received: August 08, 2022

Clinical Trial: A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Mucopolysaccharidosis (MPS)

Study Type: INTERVENTIONAL


Official Title: An Open-label, Multicenter, Phase 4 Study to Assess the Effects of a Prophylactic Immune Tolerizing Regimen in MPS II Treatment-Naïve Patients Planned to Receive ELAPRASE Who Are at Risk of Developing

Brief Summary: The main aim of this study is to evaluate the ability of a prophylactic immune tolerizing regimen (ITR) to prevent or reduce the development of high titer anti-idursulfase antibodies in treatment-naïve participants with Hunter syndrome.In this open label, single arm study, all participants will receive ELAPRASE treatment and a prophylactic ITR.Participants will be treated with ELAPRASE for up to 104 weeks.The prophylactic ITR will start 1 day prior to the start of ELAPRASE.The prophylactic ITR will consist of a…

Read more